Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juven is a specialized therapeutic nutritional supplement developed by Abbott Nutrition, designed to support tissue building and wound healing in patients recovering from surgery, injury, or chronic illness. The formulation typically contains a combination of beta-hydroxy-beta-methylbutyrate (HMB), L-arginine, and L-glutamine. HMB, a metabolite of the essential amino acid leucine, acts by stimulating protein synthesis through the mTOR pathway and inhibiting protein degradation via the ubiquitin-proteasome system, thereby helping to maintain and build lean body mass. Arginine and glutamine are conditionally essential amino acids that serve as critical substrates for collagen synthesis, immune cell proliferation, and nitrogen balance. In the clinical context of older adults undergoing hip fracture surgery, Juven is utilized as part of a comprehensive nutritional intervention to mitigate functional decline and improve post-operative recovery outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Juven.